Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, tofacitinib and baricitinib showed comparable efficacy and tolerability under unorthodox weight-stratified dosing in pediatric patients with moderate-to-severe alopecia areata over 24 weeks; however, the unorthodox baricitinib regimen yielded a lower effectiveness in severe cases, emphasizing the importance of adherence to guideline-recommended dosing.

This study found that tofacitinib and baricitinib, when administered with unorthodox weight-stratified dosing in pediatric patients with moderate-to-severe AA, showed comparable efficacy and tolerability, though baricitinib's efficacy decreased with non-standard dosing.

This article discusses the importance of integrating clinical observations with laboratory research, emphasizing the need for clinicians to collaborate with researchers to address medical problems.

Severe alopecia areata in children greatly affects their mental and social well-being, and addressing these challenges is crucial.